TABLE 2.

Diagnoses, treatments and outcomes by patient

Pati-ent	Subtype	Path. Variant	Upfront Therapy	Initial Remission/Stable Disease	Relapse/Progress-ion	Second Line Therapy	LTFU
1	UCD	HV	Resection	Y	N	N/A	N
2	UCD	Mixed	Resection	Y	N	N/A	N
3	UCD	HV	Resection	Y	N	N/A	Y
4	UCD	PCV	Resection	Y	N	N/A	N
5	UCD	HV	None	Y	N	N/A	N
6	UCD	PCV	Resection	Y	Unknown	N/A	Y
7	UCD	HV	Resection	Y	N	N/A	N
8	UCD	PCV	Resection	Y	N	N/A	Y
9	UCD	HV	Resection	Y	N	N/A	N
10	UCD	HV	Resection	Y	Unknown	Unknown	Y
11	UCD	HV	Unknown	Unknown	Unknown	Unknown	Y
12	UCD	HV	Resection	Y	Unknown	Unknown	Y
13	UCD	HV	Resection	Y	Unknown	Unknown	Y
14	UCD	HV	Resection	Y	Unknown	Unknown	Y
15	UCD	HV	Resection	Y	N	N/A	N
16	UCD	HV	Resection	Y	N	N/A	N
17	UCD	HV	Resection	Y	Unknown	Unknown	Y
18	UCD	HV	None	Unknown	Unknown	Unknown	Y
1	HHV8-neg MCD	PCV	R-CVP, tocilizumab	Y	N	N/A	N
2	HHV8-neg MCD	HV	Partial resection, R-CHOP, tocilizumab	Y	N	N/A	N
3	HHV-8 neg MCD	PCV	Partial resection, steroids	Y	N	N/A	N
4	HHV-8 neg MCD	HV	Partial resection, rituximab, steroids	N	Y	Tocilizumab (no improvement), followed by CHOP	N
5	HHV8-neg MCD	HV	Partial resection, MTX, thalidomide, steroids	N	Y	Resection	Y
6	HHV-8 neg MCD	HV	Partial resection	Y	Y	Partial Resection	N

Path, pathologic; HV, hyaline vascular; PCV, plasma cell variant; LTFU, lost to follow-up; UCD, unicentric Castleman disease; MCD, multicentric Castleman disease; R-CVP, rituximab, cyclophosphamide, vincristine, predisone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.